Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

REGENTIS BIOMATERIALS LTD.

  • Public · NYSE: RGNT
  • 8 employees
$6.8MMarket cap
-$13.6MNet income
8Employees
RGNTNYSE
2025IPO

About REGENTIS BIOMATERIALS LTD.

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$13.6M
Total assets
$7.6M
Market cap
$6.8M

Source: SEC EDGAR · updated Jun 7, 2026

NYSE: RGNT

15-minute delayed · data by Polygon.io

Market cap
$6.8M
Open
Day range
Prev close
Volume
IPO date
Dec 4, 2025

Market data by Polygon.io · prices are 15-minute delayed

No reviews yet. Be the first to review REGENTIS BIOMATERIALS LTD..

Write a review
Explore

Similar companies

Browse all →